Laboratory and Clinical Outcomes of Single Sperm Cryopreservation in Patients Underwent Micro-TESE

For men with severe oligozoospermia, sperm cryopreservation can preserve surgically obtained sperm. How to cryopreserve single sperm in men is still a hot topic in assisted reproduction technology. Aim to analyze the laboratory and pregnancy outcomes of single sperm cryopreservation group, we retrospectively selected 38 cycles underwent single sperm cryopreservation and thawing as the study group and 618 cycles underwent conventional sperm cryopreservation and thawing as the control group, which were performed in the reproductive medicine center of the Sixth Affiliated Hospital, Sun Yatsen University, from April 2014 to October 2023. All the sperm came from microdissection testicular sperm extraction (micro-TESE), and performed intracytoplasmic sperm injection (ICSI) for fertilization. Zygotes were cultured to Day 3 embryo, which were freshly transferred to female uterus. Surplus embryos were cultured to blastosphere and cryopreserved. There was no statistical difference in female/male age, female BMI, infertility duration and female basal sex hormone (FSH, LH E2, AMH), No. of oocytes retrieved per cycle, No. of ICSI oocytes per cycle and No. of embryos transferred per cycle between the two groups (P > 0.05). No significant difference was found in two-pronuclear oocyte fertilization rate (59.23% VS 58.84%), Day 3 available embryo rate (61.81% VS 63.55%), Day 3 good-quality embryo rate (45.73% VS 50.27%), blastocyst formation rate (47.83% VS 49.46%), the implantation rate (47.37% VS 52.16%), clinical pregnancy rate (36.84% VS 47.18%), miscarriage rate (14.29% VS 12.68%) and live birth rate (85.71% VS 81.70%) between two groups (P > 0.05). In conclusion, single-sperm cryopreservation was the optimal method to preserve sperm after micro-TESE. It can increase the utilization of each sperm and lead to clinical pregnancy.

四子种王胶囊联合西药治疗弱畸精症疗效及对患者抗苗勒管激素、抑制素B的影响

目的:探讨四子种王胶囊辅助西药治疗弱畸精症疗效及对患者抗苗勒管激素(AMH)、抑制素B(INHB)的影响。方法:选取弱畸精症患者180例,依据治疗方式不同分为对照组和研究组,各90例。对照组给予常规西药,研究组在对照组基础上给予四子种王胶囊治疗,两组均治疗3个月。统计两组治疗效果、不良反应及治疗前、治疗1个月、3个月后精子密度、活动率、畸形率、精子活动力(慢速直线运动、快速直线运动、原地不动)、精浆AMH、血清INHB含量、性功能障碍(IIEF-5)。结果:研究组治疗总有效率为83.33%高于对照组的70.00%(P<0.05)。治疗3个月后研究组精子密度、活动率高于对照组,畸形率低于对照组(P<0.05)。治疗3个月后研究组精子原地不动数量低于对照组,慢速直线运动及快速直线运动数量高于对照组(P<0.05)。治疗1个月、3个月后研究组AMH、INHB含量高于对照组(P<0.05)。治疗前、治疗1个月、3个月后两组IIEF-5评分比较,差异无统计学意义(P>0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:四子种王胶囊辅助西药治疗弱畸精症疗效显著,有助于上调AMH、INHB,降低精子畸形率,提高精子活率及活动力,且安全性较高。

上泳法与人工授精治疗少、弱、畸形精子不育症的价值

为提高少、弱、畸形精子症不育患者的治愈率，从1990年开始对50例药物未能治愈的少、弱、畸形精子症不有患者采用上泳法处理精子并行宫腔内人工授精治疗153个周期，结果妊娠16例，总妊娠率为32．0％，周期妊娠率为10．4％。认为尽管总妊娠率还比较抵，但对药物治疗无效的患者，此法无疑是重要的治疗方法之一。

重度少、弱、畸精症及阻塞性无精症患者单精子卵胞浆内注射治疗结果分析

目的 回顾性分析应用单精子卵胞浆内注射 (ICSI)技术治疗重度少、弱、畸精症及阻塞性无精症性不育的临床效果。方法 收集 2 0 0 1年 5月～ 2 0 0 3年 3月在我中心接受ICSI技术治疗的 2 9例 (31个周期 )重度少、弱、畸精症及 8例 (9个周期 )阻塞性无精症患者为研究对象 ,长方案进行超促排卵 ,ICSI常规操作 ,分析体外排精组和附睾取精组ICSI后的妊娠结局。结果 4 0个周期共获卵 372枚 ,平均获卵9 3± 5 36枚 ,其中可注射的MⅡ成熟卵 32 6个 (87 6 % ) ,注射后存活卵 30 6枚 (93% )。受精率 78 6 % (2 4 1/ 30 6 ) ,胚胎形成率 89% (2 15 / 2 4 1) ,优质胚胎形成率 39% (84 / 2 15 ) ,平均移植胚胎数 2 73± 0 85 ,周期生化妊娠率 35 % ,临床妊娠率 2 7 5 %。 1例 3胎、3例双胎 ,多胎率 36 % ,目前已全部出生 ,共诞生了 16名健康婴儿。结论 ICSI技术是治疗重度少、弱、畸精症及阻塞性无精症性不育的有效手段。